surf break copy_edited.jpg
surbreak-19.png
Search

Iterative Scopes brings gastrointestinal disease AI to Janssen's IBD clinical trials

Updated: Jan 27

By: Andrea Park


After chipping into its last two venture funding rounds, Johnson & Johnson is taking an even bigger chance on Iterative Scopes. The startup, which spun out of MIT in 2017, is developing artificial intelligence tools to both improve screenings for gastrointestinal diseases like colorectal cancer and inflammatory bowel disease (IBD) and boost the entire clinical trial process, including accelerating patient recruitment and improving endpoint selection. Now, J&J’s Janssen R&D division will tap those AI technologies, teaming up with Iterative Scopes to improve its own clinical trials for treatments of IBD.


CONTINUE READING

Recent Posts

See All
WM360_logo-18.png